CLRB vs CLYM

Cellectar Biosciences, Inc. vs Climb Bio, Inc. — Valuation Comparison 2026

CLRB

Biotechnology
Cellectar Biosciences, Inc.
Quality
3.7
out of 10
Value Trap
27
LOW
Price
$3.14
Last close
Models
7/13
Active
VS

CLYM

Biotechnology
Climb Bio, Inc.
Quality
4.1
out of 10
Value Trap
18
SAFE
Price
$11.34
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType CLRB Fair ValueCLRB Upside CLYM Fair ValueCLYM Upside
Bayesian DCF Intrinsic $1.39 -55.6% $3.12 -72.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.17 -93.7% $0.84 -92.6%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for CLRB vs CLYM — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CLRB vs CLYM — Which Stock Is More Undervalued?

CLYM scores higher with a 4.1/10 quality rating vs CLRB's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Cellectar Biosciences, Inc. (CLRB) and Climb Bio, Inc. (CLYM) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CLRB currently trades at $3.14 with a QOC of 3.7/10, while CLYM trades at $11.34 with a QOC of 4.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).